Table 2.
Calculation of DFs for mammary gland and uterine progestin action
| Calculation of DFa | MPA absolute DF | Drospirenone absolute DF | Drospirenone relative DFb |
|---|---|---|---|
| ED50 sidebranches/ED50 pregnancy | 1.25 (0.42, 2.86) | 2.67 (2.07, 4.36) | 2.2 (0.91, 6.84) |
| ED50 BrdU Ma./ID100 BrdU ut. | 0.44 (0.10, 1.49) | 2.89 (2.32, 3.52) | 6.66 (1.85, 20.03)c |
| ED50 BrdU Ma./ED50 pregnancy | 0.33 (0.07, 1.48) | 1.97 (1.43, 3.26) | 5.91 (1.31, 29.81)c |
| ID50 INDO Ma./ID50 LTF ut. | 0.13 (0.08, 0.21) | 0.62 (0.15, 2.84) | 4.51 (1.12, 18.31)c |
| Cyclin D1 Ma./ED50 pregnancy | 0.21 (0.14, 0.34) | 6.9 (5.7, 11.22) | 33.5 (19.91, 62.61)c |
| RANKL Ma./ED50 pregnancy | 0.21 (0.14, 0.34) | 6.9 (5.7, 11.22) | 33.5 (19.91, 62.61)c |
a
DFs are calculated by dividing quantitative measures of mammary gland action (Ma.) by those of uterine action (ut.); absolute DF values significantly larger than 1 indicate favorable dissociation of uterine and mammary gland effects.
b
Relative DFs for drospirenone were calculated as absolute DF drospirenone/absolute DF MPA.
c
Relative DF values significantly larger than 1 indicate a favorable dissociation profile of drospirenone as compared with MPA that has relative DF values of 1.